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1. Introduction 3. Problem and 
consequence 2. Delivery Systems
Nanotechnology is not new to science,
however its rather recent implementation
in drug delivery is proving to be one of
the most beneficial applications of
nanotechnology. In 2001, the National
Nanotechnology Initiative was created.
Since 2001, it has received twelve billion
dollars in funds, and just last year in
2010, was allocated 1.6 billion dollars in
federal funding [3]. This alone shows how
important nanotechnology is to research
and development.
There are several nanoparticles that can
be used for targeted drug delivery. Some
of them include: polymeric nanoparticles,
solid lipid particles, nanocrystalline
magnetic iron oxide particles, polymeric
micelles, quantum dots, dendrimers, and
phospholipid micelles [6].
The preferred route of drug delivery is via
oral delivery, however currently that
remains and issue for many drugs, and
because of that they are given
intravenously. However, through the use
of nanoparticles and their small size,
reformulation of drugs may improve their
bioavailability, allowing certain drugs to
be given orally [8]. Nanoparticles not only
allow certain drugs to be given orally,
3. Problem and consequence 3. Personalized Medicine 
Passive targeting exploits the
differences between normal and
diseased tissue. It also capitalizes on the
EPR (enhanced permeability and
retention) effect [8]. Tumors within the
body have unique characteristics. They
have unique anatomical and
physiological abnormalities, which are
caused by the EPR effect. The EPR
effect is characterized by: angiogenesis,
which is the physiological process of
growing new blood vessels from pre-
existing blood vessels, giving tumors a
much more dense vessel network. Next,
tumors have defective vasculature
architecture. They also have impaired
lymphatic drainage systems. Lastly,
tumors are known to have elevated levels
of bradykinin, nitric oxide, and
peroxynitrite [1]. Because we know
tumors exhibit these qualities due to the
EPR effect, nanoparticles can be
designed to target the tumors.
Localized delivery is the direct delivery
of drugs to tumors using nanoparticles.
This kind of delivery system is effective or
local cancers such as prostate and head
and neck cancers [8]. This kind of
targeting is showing promise for
intracellular drugs that are considered to
Personalized medicine is the new wave of medicine. It is no longer appropriate for
companies to develop drugs that only effectively treat eighty percent of patients [9].
Rather, it is now the norm to develop drugs that treat specific populations of patients.
Drug responses in patients are related by two processes: pharmacodyanmics, and
pharmacokinetics. Pharmacodyanmics measure the effects of the drug on the body,
for example drug-receptor interactions. Pharmacokinetics measure the actions by an
organism on the drug which can be drug absorption, distribution, metabolism, and
elimination [12]. These measurements can give researchers more information about
the mechanisms of drugs in the body. With this information, personalized drug
therapies can be instituted for patients. For example, in oncology patients, gene
therapy can be used to effectively treat tumors. Many cancers have been associated
with DNA methylation and the progression of the disease [5]. Using nanotechnology
to deliver DNA to targeted tumors has the potential to aid in reducing the progression
of the cancer. It can also aid to help scientists understand the mechanism of disease
progression in cancer.
Medicine can be personalized using nanotechnology. With information obtained from
genomics: pharmacokinetics and pharmacodyanmics, researchers and physicians
can predict how certain patient populations will react to a given therapy. It can also
help to identify certain biomarkers for diseases. Given this information, treatment can
be tailored to the patient. This kind of personalized medicine can reduce doses
needed of drugs, eliminate the need for certain drugs that physicians know will not
work for a patient, and help to reduce associated toxicities with certain treatments.
Multiple lines of therapies will not be needed for certain diseases, as researchers will
be able to acquire data from genomics that help to identify the most effective
treatments for a specific disease.
Figure 3: A schematic 
representing 
nanocarriers. Such 
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they also allow for drugs to be given at
lower doses. This is because
nanoparticles allow for specific targeting,
reducing the need for drugs to have to go
through the blood stream to attack
diseased tissue.
Biomaterials are widely used as
nanoparticles. Biomaterials in the body
can be used for tissue regeneration and
tissue engineering [2]. Additionally,
materials such as chitosan and diatoms
can be used in drug delivery. These types
of materials are an ideal source of
nanoparticles as they reduce the need for
synthetic materials as nanoparticles.
Nanoparticles are an ideal way to deliver
drugs to specific diseased tissues or
tumors for many reasons. They offer
lower doses, and thus lower toxicities.
Additionally, nanoparticles have longer
circulation half lives, ensuring that the
therapeutic agent will be maintained in
the body, until it is unloaded at the desire
site, and nanoparticles have more
efficient cellular uptake [4]. Nanoparticles
can infiltrate the cells of the body due to
their small size, allowing for efficient
unloading of the therapeutic agent being
delivered.
Nanotechnology is a rapidly emerging
field of science with infinite medical
applications. Nanotechnology has the
potential to revolutionize how physicians
treat their patients, and has the potential
to help improve a patient’s quality of life
while receiving treatments.
Figure 2: The schematic above details passive,
localized, and active targeting, showing how
nanoparticles can be delivered to the body (Sahoo
et al., 2007).
be pretty much insoluble, such as Taxol.
It is also promising for sensitive drugs
such as proteins, oliogonucleotides, and
DNA.
Active targeting requires active binding
to occur. It requires the binding of
receptor specific ligands to specific cells
in the body, which will promote site
specific targeting. Active targeting can
also be achieved by recognition of
diseased cells, as they have signature
molecules that are over expressed at
diseased sites [8].
Figure 1: Shows many 
different molecules at 
the nanometer size. 
Nanomedicine operates 
at a scale of about 100 
nm or less (Boisseau & 
Loubaton, 2011) 
Magnetic nanoparticles have the ability
to help with many forms of
nanotechnology. Not only for drug
delivery but also for imaging. Magnetic
nanoparticles have the ability to enhance
proton relaxation at specific tissues [10].
This can allow targeted delivery of drugs
loaded onto to the magnetic
nanoparticles, as specific tissues, such
as tumor tissue can be targeted by such
nanoparticles. Magnetic nanoparticles
can also serve as magnetic resonance
imaging contrast agents [10]. Using these
nanoparticles as contrast for MR imaging
can help to give a better view of internal
organs and tissues.
nanocarriers can be 
loaded with the desired 
drug. Certain 
nanocarriers will be 
attracted to specific 
tissues based off of the 
EPR effect (Mishra, 
Patel, & Tiwari, 2010) 
4. Drug Toxicities and Challenges 
The use of nanotechnology can help to reduce the dose needed to treat a patient, and 
thus will reduce the side effects experienced by the drugs, or at the very least, to lessen 
the degree of the toxicity. Because nanoparticles can target specific tissues in the body, 
only the amount of drug that is absolutely needed has to be used. Drugs administered in 
the body without nanoparticles are characterized by, “their poor solubility, high toxicity, 
high dosage, aggregation due to poor solubility, nonspecific delivery, in vivo degradation, 
and short circulating half-lives,” [7]. These characteristics lead to needing higher dosages 
to effectively treat a disease. Through the use of nanoparticles, the need for such high 
doses can be eliminated.
Lower doses not only lead to decreased toxicities, it also leads to an increase in a 
patient’s quality of life. Without toxicities or with limited toxicities, patients can enjoy their 
lives without worrying about being nauseous or having terrible rashes. Also, through the 
use of nanoparticles, patients won’t have to set their watch by their medication. They will 
have to take less medication, in less increments, without being constantly hindered by 
fasting or avoiding certain foods with high acidity. Loading drugs onto nanoparticles 
protects the therapeutic agents and helps the drug to make it to the desired tissue.
It is important to note however, that nanoparticles are not completely without their 
toxicities either. Nanoparticles, such as carbon nanotubes, can cause allergic reactions 
within the body [11]. There is also no way to be sure that the nanoparticles are going 
exactly to the desired area of the body, and because of their size nanoparticles can pass 
through many barriers. This leaves open the possibility that drug will be unloaded at the 
incorrect tissue.
There are no experimental procedures that are not without their potential consequences, 
however, even facing some possible toxicities due to the nanoparticles, the science 
behind nanoparticles is far more attractive than distributing the drug to patients in the 
traditional manner. 
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